Clinical Management of Inhibitors in Children With Hemophilia
Treatment strategies for children with hemophilia who have inhibitors should involve eradicating the inhibitor and managing bleeding.
All articles by Caleb Rans, PharmD
Evaluating the Cost-Effectiveness of Acute Myeloid Leukemia Treatment
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
Evaluating Factor Replacement Therapies for von Willebrand Disease
Variation in disease phenotype and clinical circumstances makes it difficult to create a standardized treatment approach to von Willebrand disease.
Evaluating the Relationship Between Atrial Fibrillation and Cancer
Patients with atrial fibrillation and cancer may be at higher risk for thromboembolic events.
Restoring T-Cell Immunity Following Allogeneic Hematopoietic Stem Cell Transplantation
Though adoptive T-cell transfer has demonstrated clinical applicability, many barriers prevent it from becoming a standard of care following transplant.
The Role of Cardiovascular Diseases in the Pathogenesis of Acquired von Willebrand Syndrome
High shear stress in blood vessels due to cardiovascular disease may be associated with the development of acquired von Willebrand syndrome.
Direct-Acting Oral Anticoagulant Treatment for Acute Venous Thromboembolism
Although clinical trials are ongoing, the safety profile and net clinical benefit of DOACs for acute venous thromboembolism treatment are unclear.
Advances in the Treatment of Hemophilia: Clinical Gene Therapy
Gene therapy with adeno-associated viral viruses could provide an efficacious, safe, and cost-effective treatment option for patients with hemophilia.
The Role of Immune Checkpoint Inhibitors in Treating Hematologic Malignancies
Immune checkpoint inhibitor therapy is associated with improved outcomes but it may also lead to serious adverse effects.
A Novel Screening Program for Severe Combined Immunodeficiency in Newborns
Population-based screening of newborns is crucial to identifying severe combined immunodeficiency before the onset of potentially fatal infection.
Next post in Bleeding Disorders
